Gorlia et al. [29] developed a prognosis model of GBM patients treated with temozolomide based on age, surgical scope, the mini-mental state evaluation score, and MGMT methylation status, which was used to assess the factors influencing GBM patient survival. This evidence concerns the gene MGMT and glioblastoma.